Hewlett Hopes Sprin...
Health Care: Drugs
Arqule Inc. (ARQL: NASDAQ)
$2.75 0.04 | 1.48%
05/23/13 - 04:00 PM ET
167.18K / 332.40K
Vol / Avg. Vol:2.67 / 2.71
Open / Prev. Close:2.65 - 2.81
Today's Range:1.98 - 6.98
52 Wk Range:-0.36%
Performance YTD:TheStreet Rating:
Portfolios with ARQL
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserD-ZYRE
- User2012 picks 10/28/20121
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
Latest ARQL Headlines from TheStreet
- 5 Under-$10 Stocks Setting Up to Trade Higher 11.30.12 | 12:11 pm
- 5 Stocks Poised for Breakouts 10.26.12 | 01:10 pm
- Stocks Drop on Eurozone, Earnings Anxieties 10.02.12 | 02:10 pm
- Arqule Shutters Lung Cancer Study Early Due to Futility 10.02.12 | 07:10 am
- Arqule Shares Slide on Lung Cancer Drug Safety Concern 08.29.12 | 10:08 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- 3 Stocks Under $10 Moving Higher 04.03.12 | 12:04 pm
Press Releases for ARQL
- ArQule Reports Fiscal 2012 Year End And Fourth Quarter Results - Business Wire 03.14.13 | 07:03 am
- ArQule To Report Fiscal 2012 Financial Results On March 14, 2013 - Business Wire 03.07.13 | 08:03 am
- ArQule, Inc. To Present At Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.27.13 | 08:02 am
- ArQule, Inc. To Present At RBC Capital Markets Global Healthcare Conference - Business Wire 02.19.13 | 08:02 am
- ArQule, Inc. To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.07.13 | 08:02 am
- Daiichi Sankyo And ArQule Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial For Tivantinib - Business Wire 01.31.13 | 08:01 am
- Daiichi Sankyo And ArQule Announce Top-Line Results Of Phase 2 Trial With Tivantinib In Colorectal Cancer - Business Wire 01.11.13 | 07:01 am
- ArQule Enrolls First Patient In Phase 1 Trial With ARQ 087, An FGFR Inhibitor - Business Wire 12.13.12 | 08:12 am
- ArQule, Inc. To Present At Oppenheimer Healthcare Conference - Business Wire 12.05.12 | 04:12 pm
- ArQule, Inc. To Present At Lazard Healthcare Conference - Business Wire 11.07.12 | 08:11 am
Partner Headlines for ARQL
- ArQule Earnings: Everything You Must Know Now - Wall St. Cheat Sheet 05.08.13 | 10:05 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.03.12 | 09:10 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 08.07.12 | 09:08 am
- Teradyne DROPS 16% in Recent Weeks and 4 Fresh Analyst Insights - Wall St. Cheat Sheet 07.06.12 | 01:07 pm
- Five Stocks With Heavy Insider Trading - Benzinga 06.11.12 | 01:06 pm
- Stock Insights: Dendreon, Medtronic, FedEx, ArQule, Rentrak June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- ArQule Announces Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 05.01.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 04.02.12 | 09:04 am
